959 1030
Financial disclosures:
Bernard H. Bochner certifies that all conflicts of
interest, including specific financial interests and relationships and
affiliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/affiliation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony, royalties,
or patents filed, received, or pending), are the following: None.
Funding/Support and role of the sponsor:
Supported by The Sidney
Kimmel Center for Prostate and Urologic Cancers, the Michael and Zena
Wiener for Therapeutics Program in Bladder Cancer, Pin Down Bladder
Cancer, the Marie-Jose´e and Henry R. Kravis Center for Molecular
Oncology, and the National Cancer Institute Cancer Center Core Grant
Number P30-CA008748.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
http://dx.doi.org/10.1016/j. eururo.2017.05.032.
References
[1]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86.
[2]
Schned AR, Andrew AS, Marsit CJ, Kelsey KT, Zens MS, Karagas MR, et al. Histological classification and stage of newly diagnosed bladder cancer in a population-based study from the Northeastern United States. Scand J Urol Nephrol 2008;42:237–42.[3]
Chamie K, LitwinMS, Bassett JC, et al. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer 2013;119:3219–27.
[4]
van den Bosch S, AlfredWitjes J. Long-termcancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 2011;60:493–500.
[5]
Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 2015;15:25–41.
[6]
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507: 315–22.[7]
Kim PH, Cha EK, Sfakianos JP, et al. Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. Eur Urol 2015;67:198–201.
[8]
Cazier JB, Rao SR, McLean CM, et al. Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinico- pathological associations with mutation burden. Nat Commun 2014;5:3756.[9]
Nordentoft I, Lamy P, Birkenkamp-Demtro¨der K, et al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep 2014;7:1649–63.
[10]
Balbas-Martinez C, Sagrera A, Carrillo-de-Santa-Pau E, et al. Recur- rent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet 2013;45:1464–9.[11]
Guo G, Sun X, Chen C, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013;45:1459–63.[12]
Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering- Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 2015;17:251–64.[13]
Solomon DA, Kim T, Diaz-Martinez LA, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 2011;333: 1039–43.[14]
Taylor CF, Platt FM, Hurst CD, Thygesen HH, Knowles MA. Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromo- somal copy number changes. Hum Mol Genet 2014;23:1964–74.[15]
Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R, The FGFR. landscape in cancer: analysis of 4,853 tumors by next-gen- eration sequencing. Clin Cancer Res 2016;22:259–67.
[16]
Williams SV, Hurst DC, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013;22:795–803.
[17]
Sfakianos JP, Cha EK, Iyer G, et al. Genomic characterization of upper tract urothelial carcinoma. Eur Urol 2015;68:970–7.[18]
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–20.[19]
Desai NB, Scott SN, Zabor EC, et al. Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer 2016;122:3715–23.[20]
Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014;4:1140–53.[21]
Stadler ZK,Battaglin F,Middha S, et al. Reliable detection ofmismatch repair deficiency in colorectal cancers using mutational load in next- generation sequencing panels. J Clin Oncol 2016;34:2141–7.
[22]
Zhou X, Zhang G, Tian Y. p53 status correlates with the risk of recurrence in non-muscle invasive bladder cancers treated with bacillus Calmette-Guerin: a meta-analysis. PLoS One 2015;10: e0119476.[23]
Allory Y, Beukers W, Sagrera A, et al. Telomerase reverse transcrip- tase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 2014;65:360–6.[24]
Hurst CD, Platt FM, Knowles MA. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol 2014;65:367–9.[25]
Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532–43.[26]
Balbas-Martinez C, Rodrı´guez-Pinilla M, Casanova A, et al. ARID1A alterations are associated with FGFR3 -wild type, poor-prognosis, urothelial bladder tumors. PLoS One 2013;8:e62483.[27]
Bitler BG, Aird KM, Garipov A, et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A -mutated cancers. Nat Med 2015;21:231–8.
[28]
Bartek J, Lukas J, Bartkova J. DNA damage response as an anti-cancer barrier: damage threshold and the concept of ‘‘conditional haploinsufficiency’’. Cell Cycle 2007;6:2344–7.[29]
Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer–a current perspective. Nat Rev Urol 2014;11:153–62.[30]
Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401–4.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 9 5 2 – 9 5 9
959